Rastinejad F - Search Results

1

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. Good DJ, et al. Among authors: rastinejad f. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624-8. doi: 10.1073/pnas.87.17.6624. Proc Natl Acad Sci U S A. 1990. PMID: 1697685 Free PMC article.

2

Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.

Rastinejad F, Polverini PJ, Bouck NP. Rastinejad F, et al. Cell. 1989 Feb 10;56(3):345-55. doi: 10.1016/0092-8674(89)90238-9. Cell. 1989. PMID: 2464438

3

Assay and purification of naturally occurring inhibitor of angiogenesis.

Polverini PJ, Bouck NP, Rastinejad F. Polverini PJ, et al. Among authors: rastinejad f. Methods Enzymol. 1991;198:440-50. doi: 10.1016/0076-6879(91)98044-7. Methods Enzymol. 1991. PMID: 1857235 No abstract available.

4

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG. Beebe JS, et al. Among authors: rastinejad f. Cancer Res. 2003 Nov 1;63(21):7301-9. Cancer Res. 2003. PMID: 14612527

5

Pharmacological rescue of mutant p53 conformation and function.

Foster BA, Coffey HA, Morin MJ, Rastinejad F. Foster BA, et al. Among authors: rastinejad f. Science. 1999 Dec 24;286(5449):2507-10. doi: 10.1126/science.286.5449.2507. Science. 1999. PMID: 10617466

6

The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.

Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. Takimoto R, et al. Among authors: rastinejad f. Cancer Biol Ther. 2002 Jan-Feb;1(1):47-55. doi: 10.4161/cbt.1.1.41. Cancer Biol Ther. 2002. PMID: 12174820

7

Structural and functional basis for therapeutic modulation of p53 signaling.

Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Bassett EA, et al. Among authors: rastinejad f. Clin Cancer Res. 2008 Oct 15;14(20):6376-86. doi: 10.1158/1078-0432.CCR-08-1526. Clin Cancer Res. 2008. PMID: 18927276 Review.

8

Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.

Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Wang W, et al. Among authors: rastinejad f. Mol Cell Biol. 2003 Mar;23(6):2171-81. doi: 10.1128/MCB.23.6.2171-2181.2003. Mol Cell Biol. 2003. PMID: 12612087 Free PMC article.

9

Restoring p53-dependent tumor suppression.

Wang W, Rastinejad F, El-Deiry WS. Wang W, et al. Among authors: rastinejad f. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S55-63. Cancer Biol Ther. 2003. PMID: 14508081 Review.

10

CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death.

Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. Wischhusen J, et al. Among authors: rastinejad f. Oncogene. 2003 Nov 13;22(51):8233-45. doi: 10.1038/sj.onc.1207198. Oncogene. 2003. PMID: 14614447

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page